DIAZOXIDEH

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究将探讨二氮嗪（通过中枢机制发挥作用）对抑制肝脏内源性葡萄糖生成的潜在影响，并研究其作为糖尿病治疗药物的用途。 我们将确定在激素水平固定的情况下，二氮嗪对非糖尿病、健康、年轻个体的肝葡萄糖生成的影响。 在“胰腺钳夹”研究期间测量葡萄糖产生速率，在实验条件下，在存在正常血糖（血糖约90 mg/dl）的情况下，输注生长抑素和基础激素替代。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The study will address the potential impact of diazoxide, which acts via a central mechanism, on inhibiting endogenous glucose production in the liver, and to investigate its use as treatment for diabetes melitus. We will determine the effect of diazoxide on hepatic glucose production in nondiabetic, healthy, young individuals under fixed hormonal conditions. Rates of glucose production will be measured during "pancreatic clamp" studies, with somatostatin infusion and basal hormone replacement in the presence of normoglycemia (plasma glucose ~90 mg/dl) under experimental conditions.